Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated A and is the 24th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
SHC	SOTERA HEALTH CO	$4.93B	284,093,929	80.22%	19.78%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$51.80B	79,851,330	90.09%	1.78%	Net Buying	Net Buying
ILMN	ILLUMINA INC	$17.78B	152,800,000	93.44%	6.56%	Net Buying	Net Selling
LH	LABCORP HOLDINGS INC	$24.03B	82,900,000	92.85%	1.54%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$28.31B	20,325,250	95.44%	4.56%	Net Buying	Net Buying
A	AGILENT TECHNOLOGIES INC	$36.54B	283,498,871	88.44%	1.26%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$12.03B	28,381,283	26.85%	73.15%	Net Selling	Net Selling
CAI	CARIS LIFE SCIENCES INC	$6.07B	282,146,923	34.47%	65.53%	Net Selling	Net Buying
DHR	DANAHER CORP	$155.38B	706,349,563	75.77%	24.23%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$311.16M	107,741,467	1.32%	0.00%
NEOG	NEOGEN CORP	$2.34B	217,525,981	98.00%	2.00%	Net Buying	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.17B	49,215,471	96.48%	3.52%	Net Buying	Net Selling
DGX	QUEST DIAGNOSTICS INC	$23.29B	111,242,362	94.13%	1.77%	Net Selling	Net Selling
CDNA	CAREDX INC	$1.01B	51,432,639	77.47%	22.53%	Net Selling	Net Selling
PRPO	PRECIPIO INC	$37.67M	1,752,007	1.28%	98.72%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$198.06B	375,708,059	88.06%	0.91%	Net Buying	Net Buying
QGEN	QIAGEN NV	$11.11B	217,685,000	77.09%	0.00%
IQV	IQVIA HOLDINGS INC	$30.12B	170,000,000	53.18%	46.82%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$452.09M	93,213,722	91.05%	8.95%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$710.99M	30,912,392	55.73%	41.65%	Net Selling	Net Selling
WAT	WATERS CORP	$19.60B	59,534,740	92.19%	7.81%	Net Selling	Net Selling
ICLR	ICON PLC	$10.17B	76,359,932	97.40%	0.00%
BLLN	BILLIONTOONE INC	$3.92B	45,768,760	0.04%	26.06%	Net Buying
RVTY	REVVITY INC	$11.46B	113,375,621	97.27%	2.73%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$13.56B	126,041,089	66.10%	33.90%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	$1.48B	129,387,801	72.70%	27.30%	Net Buying	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$367.29M	108,345,239	56.97%	43.03%	Net Selling	Net Selling
GRAL	GRAIL INC	$3.91B	38,982,223	63.66%	21.22%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	$297.36M	13,895,394	9.33%	0.00%
CSTL	CASTLE BIOSCIENCES INC	$943.96M	29,188,659	85.51%	14.49%	Net Selling	Net Selling
BDSX	BIODESIX INC	$82.34M	7,955,685	3.47%	96.53%	Net Buying	Net Buying
RDNT	RADNET INC	$5.36B	77,146,342	70.67%	29.33%	Net Selling	Net Buying
MYNZ	MAINZ BIOMED NV	$3.47M	4,091,853	11.78%	16.90%	Net Buying
NTRA	NATERA INC	$29.32B	138,014,465	80.11%	19.89%	Net Selling	Net Selling
XGN	EXAGEN INC	$74.79M	22,663,099	39.94%	49.06%	Net Selling
TWST	TWIST BIOSCIENCE CORP	$3.04B	61,311,704	88.41%	11.59%	Net Selling	Net Selling
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$164.25M	28,664,437	16.58%	83.42%	Net Selling
PSNL	PERSONALIS INC	$790.36M	88,804,348	64.17%	35.83%	Net Selling	Net Buying
OPK	OPKO HEALTH INC	$959.63M	767,701,280	19.98%	80.02%	Net Buying	Net Buying
MDXH	MDXHEALTH SA	$17.62M	49,497,334	24.08%	75.92%
STIM	NEURONETICS INC	$123.27M	68,485,922	30.87%	32.09%	Net Selling
LAB	STANDARD BIOTOOLS INC	$457.63M	384,565,414	54.36%	45.64%	Net Buying	Net Buying
FONR	FONAR CORP	$122.37M	6,585,978	44.16%	3.58%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.47M	4,498,709	5.91%	94.09%
NDRA	ENDRA LIFE SCIENCES INC	$4.21M	1,166,441	1.05%	98.95%	Net Buying
EXAS	EXACT SCIENCES CORP	$19.60B	189,471,298	94.18%	3.51%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$3.03M	9,771,028	3.51%	66.08%
MBAI	CHECK-CAP LTD	$281.13M	151,962,777	0.02%	0.00%
NOTV	INOTIV INC	$10.80M	34,394,971	23.15%	39.02%	Net Selling	Net Selling
SERA	SERA PROGNOSTICS INC	$99.96M	38,594,793	47.04%	25.17%	Net Selling	Net Selling
VNRX	VOLITIONRX LTD	$27.51M	122,801,572	21.27%	31.35%	Net Buying	Net Buying
TRIB	TRINITY BIOTECH PLC	$15.20M	369,329,458	0.73%	0.00%
XWEL	XWELL INC	$2.25M	5,766,703	1.25%	98.75%
DRIO	DARIOHEALTH CORP	$74.45M	6,768,184	5.40%	94.60%	Net Buying
BNBX	BNB PLUS CORP	$3.75M	4,365,541	0.32%	99.68%
ADVB	ADVANCED BIOMED INC	$5.35M	21,640,000	1.21%	0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Feb 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 27, which is 1 points higher than the diagnostic & research industry average of 26.

SHC passed 9 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 26.88% over the past year, overperforming other diagnostic & research stocks by 19 percentage points.

Sotera Health Co has an average 1 year price target of $21.00, an upside of 20.9% from Sotera Health Co's current stock price of $17.37.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 50% have issued a Strong Buy rating, 25% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 39.89% over the past year, overperforming other diagnostic & research stocks by 32 percentage points.

Idexx Laboratories has an average 1 year price target of $765.71, an upside of 18.03% from Idexx Laboratories's current stock price of $648.73.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 11 points higher than the diagnostic & research industry average of 26.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 15.59% over the past year, overperforming other diagnostic & research stocks by 8 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 19.09% from Illumina's current stock price of $116.38.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.53%, which is 1 percentage points higher than the diagnostic & research industry average of 0.75%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.99%, which is the same as the diagnostic & research industry average of 0.75%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.78%, which is the same as the diagnostic & research industry average of 0.75%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.6% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.3% in the last day, and down -4.76% over the last week. Insight Molecular Diagnostics was the among the top losers in the diagnostics & research industry, dropping -22.67% yesterday.

Insight Molecular Diagnostics shares are trading lower after the company announced a $26.0 million offering of 4.526 million shares at $5.75 per share.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -28.94% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 29.99% in the past year. It has overperformed other stocks in the diagnostic & research industry by 22 percentage points.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Illumina has a valuation score of 14, which is -1 points higher than the diagnostic & research industry average of 15. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates ILMN a Valuation Rating of "B".

Illumina's stock has gained 15.59% in the past year. It has overperformed other stocks in the diagnostic & research industry by 8 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 18.45% over the next year.

4.76% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 26.19% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 2.38% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 21.05x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Sotera Health Co (NASDAQ:SHC)

2. Idexx Laboratories (NASDAQ:IDXX)

3. Illumina (NASDAQ:ILMN)

1. Quest Diagnostics (NYSE:DGX)

2. Labcorp Holdings (NYSE:LH)

3. Agilent Technologies (NYSE:A)

1. Icon (NASDAQ:ICLR)

2. Qiagen Nv (NYSE:QGEN)

3. Illumina (NASDAQ:ILMN)

Company

Stock Tools

Stock Ideas